Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
1.
Journal of Korean Medical Science ; : 1296-1304, 2010.
Artigo em Inglês | WPRIM | ID: wpr-177039

RESUMO

In the present study, we investigated whether and how the mineralocorticoid receptor antagonist spironolactone affects cardiac growth and development through apoptosis and cell proliferation in the neonatal rat heart. Newborn rat pups were treated with spironolactone (200 mg/kg/d) for 7 days. The cell proliferation was studied by PCNA immunostaining. The treatment with spironolactone decreased proliferating myocytes by 32% (P<0.05), and reduced myocytes apoptosis by 29% (P<0.05). Immunoblot and immunohistochemistry for the expression of p38, p53, clusterin, TGF-beta2, and extracellular signal-regulated kinase were performed. In the spironolactone group, p38, p53, clusterin, and TGF-beta2 protein expression was significantly decreased (P<0.05). These results indicate that aldosterone inhibition in the developing rat heart induces cardiac growth impairment by decreasing proliferation and apoptosis of myocytes.


Assuntos
Animais , Feminino , Ratos , Antagonistas de Receptores de Mineralocorticoides/farmacologia , Animais Recém-Nascidos , Apoptose , Proliferação de Células , Clusterina/genética , Coração/efeitos dos fármacos , Antígeno Nuclear de Célula em Proliferação/metabolismo , Ratos Sprague-Dawley , Espironolactona/farmacologia , Fator de Crescimento Transformador beta2/genética , Proteína Supressora de Tumor p53/genética , Proteínas Quinases p38 Ativadas por Mitógeno/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA